Nikolai A. Podoltsev

Yale Cancer Center — United States

Medicine · Health Sciences

36h-index5.9kcitations296works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(150), Myeloproliferative Neoplasms: Diagnosis and Treatment(84), Chronic Myeloid Leukemia Treatments(62), Chronic Lymphocytic Leukemia Research(39), Acute Lymphoblastic Leukemia research(38)

Publications296 total

Thrombo-inflammatory endothelial signatures in <i>JAK2</i> -mutated myeloproliferative neoplasms
2026Open Access
Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia
Leukemia Research·2025
The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of A phase I study
Blood·2025Open Access
Large language models mediated extraction of clinical information from bone marrow biopsy pathology reports
Blood·2025
Prospective evaluation of an AI-powered clinical trial patient matching (CTPM) system in myelodysplastic syndromes (MDS) and multiple myeloma
Blood·2025Open Access
Assessing the influence of live and online enduring CME activities presented at the 66th ASH annual meeting on hematology/oncology specialists using pre-/post-education evaluations
Blood·2025
Clinical, cytogenetic and molecular predictors of early mortality in acute promyelocytic leukemia (APL): Real-world analysis
Blood·2025Open Access
Early discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy
Blood·2025Open Access
Acute myeloid leukemia (AML) after myeloproliferative neoplasm (MPN): Real-world outcomes in the new AML treatment era
Blood·2025
Clinical characteristics, disease progression, and vascular events in essential thrombocythemia: A single-center cohort study with long-term follow-up.
Blood·2025
Validation of the international working group (IWG) 2023 criteria for clinical benefit in higher risk Myelodysplastic Syndromes (HR-MDS) using a large, international, randomized Phase 3 clinical trial dataset
Blood·2025Open Access
Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy
Blood·2025· 1 cited
Treatment initiation and first line tyrosine kinase inhibitor (TKI) selection for older patients with newly diagnosed chronic myeloid leukemia (CML) in the United States (US) before and after the introduction of generic imatinib (GE-IMA)
Blood·2025Open Access
Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab
Blood·2025
Phase II Results of ECOG-ACRIN EA9152: A multicenter study of liposomal vincristine (L-VCR) or vincristine sulfate (VCR) and venetoclax (VEN) in relapsed or refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL)
Blood·2025Open Access
Pacritinib in patients with high-risk myelofibrosis: Outcomes from post-hoc analyses of two Phase 3 studies
Blood·2025
Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial
Blood·2025Open Access
Menin inhibitors for NPM1-mutated and KMT2A-rearranged relapsed/refractory acute myeloid leukemia (AML): A systematic review and meta-analysis
Blood·2025Open Access
Impact of metformin on the incidence of thrombotic events in older patients with polycythemia vera and essential thrombocythemia in the United States
Blood·2025
Clonal persistence and early cooperative mutations shape transformation in myelofibrosis
Blood·2025Open Access
page 1 of 15Next →

Frequent Co-authors

Amer M. Zeidan(21), Steven D. Gore(16), Scott F. Huntington(10), Amy J. Davidoff(10), Maximilian Stahl(9), Rory M. Shallis(9), Jan Philipp Bewersdorf(9), Rong Wang(9), Alexander E. Perl(8), Xiaomei Ma(8), Pau Montesinos(7), Mark J. Levis(7), Gail J. Roboz(7), Jason Gotlib(7), Sanjay Mohan(7), Martha Wadleigh(7), Smith Giri(7), Catriona Jamieson(6), Krishna Gundabolu(6), Stephen T. Oh(6)